Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MK-8745 |
Synonyms | |
Therapy Description |
MK-8745 is selective Aurora A kinase inhibitor, which induces cell cycle arrest (PMID: 21879811). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-8745 | Aurka Inhibitors 27 | MK-8745 is selective Aurora A kinase inhibitor, which induces cell cycle arrest (PMID: 21879811). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
TP53 del | colorectal cancer | predicted - sensitive | MK-8745 | Preclinical - Cell culture | Actionable | In a preclinical study, MK-8745 treatment resulted in polyploidy in TP53-null colorectal cancer cells in culture (PMID: 22293494). | 22293494 |
TP53 wild-type | colorectal cancer | predicted - sensitive | MK-8745 | Preclinical - Cell culture | Actionable | In a preclinical study, MK-8745 treatment resulted in apoptosis in Tp53 wild-type colorectal cancer cells in culture (PMID: 22293494). | 22293494 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|